Wave Life Sciences could offer significant upside if obesity candidate WVE-007 delivers strong human data. Check out the ...

日前，谷歌旗下抗衰老公司 Calico Life Sciences 宣布与 迈威生物 （Mabwell）达成一项总价近6 亿美元的生物制药交易，以获取针对白介素-11（IL-11）的研究性疗法权益，其中包括一种用于治疗年龄相关疾病的临床阶段单克隆抗体 ...

6月27日，迈威生物（688062）公告称，公司与CALICO LIFE SCIENCES LLC.拟就IL-11靶向治疗（包括9MW3811）签署《独家许可协议》。根据许可协议，迈威生物独家许可CALICO在除大中华区以外的所有区域内独家开发、生产和商业化许可产品的权利。公司可获得首付款及里程碑付款，以及按许可产品净销售额计算的阶梯式特许权使用费。

Investing.com - Aegis Capital在atai Life Sciences N.V (NASDAQ: ATAI )的BPL-003治疗难治性抑郁症 (TRD)取得积极的2b期试验结果后，重申了其"买入"评级和8.00美元的目标价。该股票表现出显著的增长势头，过去一年上涨超过100%，分析师目标价格范围在6美元至12美元之间。 InvestingPro ...

Investing.com - H.C. Wainwright在atai Life Sciences N.V (NASDAQ: ATAI )的抑郁症治疗药物取得积极的2b期临床试验结果后，重申了对该公司的买入评级和10.00美元的目标价。根据 InvestingPro 数据，分析师目标价格区间为6美元至12美元，目前该股交易价格接近其52周高点2.90美元。

其一，迈威生物与谷歌母公司Alphabet旗下抗衰老研究公司Calico Life Sciences（以下简称 ...

While retrieval augmented generations (RAGs) and agents grab attention, what’s next is really a search across your data.

A European pharma trade organisation has said that a new strategy launched by the EU to bolster the region's standing in life ...

Wave Life Sciences Ltd. (NASDAQ:WVE) ranks among the best CRISPR stocks to buy. On June 23, H.C. Wainwright maintained its ...

Achieve Life Sciences (NASDAQ:ACHV) has announced the pricing of an underwritten public offering of 15M shares of its common ...

In a field where scientific innovation saves lives, researchers still spend an astonishing 42% of their time on ...

Earlier this week, hundreds of the industry’s finest descended on the Hilton Bankside hotel in London for the inaugural Life ...